On March 13, 2017, Apotex filed for leave to appeal the Federal Court of Appeal’s (FCA) decision addressing validity and infringement of AstraZeneca’s Canadian Patent No. 1,292,693 (the 693 Patent) (reported here) with the Supreme Court of Canada (SCC).
March 22, 2017
The Ontario Superior Court of Justice dismissed the defendants’ motion for summary judgment in Apotex’s action for s. 8 damages.
March 20, 2017
As we reported, Teva Canada Ltd. was awarded damages pursuant to section 8 of the Regulations after Pfizer’s prohibition application under section 6 of the Regulations relating to an extended release formulation of venlafaxine hydrochloride
January 23, 2017
The Federal Court of Appeal upheld findings of the Federal Court declaring the asserted claims of Canadian Patent No. 1,292,693 to be valid and infringed by Apotex’s manufacture, sale, and promotion of Apo-Omeprazole capsules, a generic version of AstraZeneca’s LOSEC®, but allowed Apotex’s appeal in respect of the appropriate limitation period for infringing activities.
January 18, 2017
The Federal Court found that Apotex and Cobalt’s generic versions of Bayer’s combination oral contraceptives marketed in Canada as YAZ and YASMIN infringe Bayer’s patent.
November 16, 2016
Amgen Canada Inc. and Amgen Inc. (collectively, Amgen) market and sell filgrastim in Canada under the name NEUPOGEN® for use in the treatment of neutropenia.
August 11, 2016
This decision is an appeal from a judgement of the Federal Court declining to vary its decision awarding damages to Apotex under section 8 of the Regulations.
July 14, 2016
On April 20, 2015, the Supreme Court heard Sanofi-Aventis’ appeal of the Federal Court of Appeal section 8 quantification decision with respect to the drug Ramipril.
April 29, 2015
The Supreme Court of Canada has refused Teva’s application for leave to appeal the decision of the Federal Court of Appeal.
November 17, 2014
The Supreme Court of Canada announced yesterday that it has granted leave to appeal the decision of the Federal Court of Appeal in a proceeding commenced by Apotex.
October 31, 2014
Try searching our global site instead